Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04434482
Title IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Impact Therapeutics, Inc.

ovarian cancer

castration-resistant prostate carcinoma

prostate cancer

Advanced Solid Tumor

triple-receptor negative breast cancer

lung small cell carcinoma


Senaparib + Temozolomide

Age Groups: adult | senior
Covered Countries

No variant requirements are available.